Pricing Log in Create free account
Saturday 17 October 2026 Export ZCMD’s income statement to Excel — free account

Zhongchao Inc.

ZCMD Healthcare Health Information Services

Zhongchao Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.4 million, down 28.3% from fiscal 2024.

1.29 0.10 −7.19%
Market cap
$6.2M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
3/9
Altman Z
9.11
Beneish M
−4.20
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 88.17%

Capital & Financial Ratios $m

Market Cap 6.16
Revenue 32.21
Net Income (6.77)
Free Cash Flow (4.10)
Net Debt (13.92)
Current Ratio 11.11 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E —
P/S ratio 0.00
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth —
Next Y EPS Growth —
Next Y revenue growth 20.94% (at or above 10%: strong)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.4×, against a ten-year median of −0.4×; over the ten years it ranged from −0.5× in 2020 to −0.3× in 2022.
EV/FCF against its own 10 years 52.12%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2020 Powerpack
2019 Powerpack
2018 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2022 2023 2024 2025
Cash 12 13 13 14
Receivables 7 3 5 3
Inventory 0 1 1 —
Other 0 0 0 0
23 19 19 17
2022 2023 2024 2025
Payables 0 1 1 1
ST’ Debt — — — —
Other 0 1 0 0
4 3 2 2

Compound Annual Growth %

10y 5y 3y
Sales — (8.76%) (7.02%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (6.62%) (11.87%)

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — 11
’24 — — — — 16
’23 — — — — 19
’22 — — — — 14
’21 — — — — 16
’20 — — — — 18
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — 1
’24 — — — — (1)
’23 — — — — 0
’22 — — — — (1)
’21 — — — — 3
’20 — — — — (1)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — 2 — 1 1
’24 — (1) — (5) (5)
’23 — (2) — (1) (1)
’22 — (1) — (1) (1)
’21 — 0 — 1 1
’20 — (3) — (1) (1)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — (171.84)
’24 — — — — (89.17)
’23 — — — — (3.23k)
’22 — — — — (817.42)
’21 — — — — 74.31
’20 — — — — 1.34k
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — 8,754.65 21,724.80 8,928.00 4,642.56 1,488.00 522.29

Analyst estimates 2026–2028

Powerpack
High — — — — 78,120.00 60,859.20 28,272.00 20,832.00 7,588.80 3,392.64
People
People Employees — — 90 91 88 136 109 142 111 33
Revenue/emp, $m — 0.00 0.14 0.16 0.20 0.12 0.13 0.14 0.14 0.34
Income, $m
Income, $m Revenue — 10 13 15 18 16 14 19 16 11
Gross margin, % — 59.56 65.36 68.72 65.99 57.92 44.92 43.80 56.18 45.02
EBT — 1 4 4 5 0 (3) (12) 0 (6)
EBT margin, % — 13.66 27.23 29.48 27.47 (0.68) (18.02) (61.63) 0.39 (50.71)
Net income — 0 3 4 4 0 (3) (11) 0 (6)
Depreciation — 0 0 0 0 0 0 1 0 0
Per share, $
Per share, $ Revenue — 0.39 4,594.96 5,132.00 5,451.45 4,793.18 4,043.29 5,552.54 2,266.40 309.10
Earnings — 0.06 1,074.18 1,411.91 1,337.60 74.31 (817.42) (3,232.52) (89.17) (171.84)
Cash flow — (0.02) 468.79 485.52 (314.48) 841.71 (189.06) 15.49 (210.46) 22.97
Capex — 0.00 (388.07) (452.72) (48.67) (529.38) (143.86) (230.89) (435.03) (4.15)
Free cash flow — (0.02) 80.71 32.79 (363.15) 312.32 (332.91) (215.40) (645.49) 18.83
Book value — 0.21 4,066.21 5,289.14 9,646.70 9,578.35 9,434.09 6,010.91 3,450.16 614.08
Shares, m — 25 0 0 0 0 0 0 0 0
Valuation, ×
Valuation, × P/E — 25.00 25.00 25.00 74,400.00 139,402.11 0.00 0.00 0.00 0.00
P/S — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/B — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Sales — 0.00 0.00 0.00 (0.50) (0.39) (0.37) (0.39) (0.38) (0.41)
EV/FCF — 0.00 0.00 0.00 2.94 4.63 9.54 2.76 1.47 3.22
Cash, $m
Cash, $m Operating cash flow — (1) 1 1 (1) 3 (1) 0 (1) 1
Capex — 0 (1) (1) 0 (2) (1) (1) (3) 0
Free cash flow — (1) 0 0 (1) 1 (1) (1) (5) 1
Balance, $m
Balance, $m Working capital — 5 10 12 27 24 19 16 17 15
Total debt — — 1 0 0 0 0 — — —
Net debt — (5) (8) (8) (17) (14) (12) (13) (13) (14)
Shareholders’ equity — 5 11 15 32 33 33 21 24 23
Returns, %
Returns, % ROA — 14.55 42.99 25.46 16.97 0.67 (7.85) (35.97) (2.56) (25.22)
ROIC — 0.00 67.54 30.33 19.05 (1.09) (8.80) (109.36) (1.93) (44.60)
ROE — 18.40 36.39 30.29 18.90 0.74 (8.97) (41.94) (2.85) (27.00)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jan 0001

Charts ten years each

Zhongchao Inc. vs peers in Health Information Services (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RNLXY Renalytix plc - Sponsored ADR $17.2M — (loss-making) — +13.73% (above 0%: growing) n/m +17.96% (above 0%: growing) 19.16% (783.91%) Compare
BFRG Bullfrog AI Holdings Inc. $9.9M — (loss-making) — +2,054.00% (above 0%: growing) n/m −5.67% (below 0%: shrinking) 49.63% (658.82%) Compare
ETAOF ETAO International Co., Ltd. $9.8M — (loss-making) — — n/m +37,595.70% (above 0%: growing) — 0.00% Compare
HCTI Healthcare Triangle, Inc. $7.4M 0.0× — (loss-making) +158.38% (above 0%: growing) n/m +67.48% (above 0%: growing) 22.48% (44.28%) Compare
MGRX Mangoceuticals, Inc. $7.1M — (loss-making) — −59.07% (below 0%: shrinking) n/m +79.27% (above 0%: growing) 64.24% (1,501.45%) Compare
HLTHQ Cue Health Inc. $6.9M — (loss-making) — (loss-making) −87.19% (below 0%: shrinking) n/m +50.55% (above 0%: growing) (90.14%) (792.13%) Compare
ZCMD Zhongchao Inc. $6.2M — (loss-making) — +20.44% (above 0%: growing) −550.00% (below 0%: shrinking) +191.85% (above 0%: growing) 41.67% 0.00%
ACON Aclarion, Inc. $5.6M — (loss-making) — (loss-making) +30.57% (above 0%: growing) n/m −41.41% (below 0%: shrinking) 32.94% (11,506.75%) Compare
VSEED VSee Health, Inc. $2.8M — (loss-making) — (loss-making) +48.02% (above 0%: growing) n/m −257.62% (below 0%: shrinking) 13.20% (172.69%) Compare
Median of peers $7.3M — — +30.57% — +34.25% 22.48% (721.36%)

All 51 Health Information Services stocks →

Zhongchao Inc. (ZCMD) key facts

  • Concern: Zhongchao Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.4 million, down 28.3% from fiscal 2024.
  • Concern: Zhongchao Inc. reported a net loss of $5.8 million, or a loss of $171.84 per share, for fiscal 2025.
  • Zhongchao Inc. (ZCMD) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, ZCMD traded at $1.29, a market capitalization of $6.2 million.
  • Return on equity was −27.0% and debt-to-equity 0.00.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 9.11 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Zhongchao Inc. (ZCMD) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/ZCMD · Data as of Jan 3, 0001 · For information only; not investment advice. · © 2026 stockrow.com